[go: up one dir, main page]

WO2018125019A3 - Utilisation de certains miarn destinés au diagnostic et au traitement de maladies associées à l'insuline - Google Patents

Utilisation de certains miarn destinés au diagnostic et au traitement de maladies associées à l'insuline Download PDF

Info

Publication number
WO2018125019A3
WO2018125019A3 PCT/TR2017/050737 TR2017050737W WO2018125019A3 WO 2018125019 A3 WO2018125019 A3 WO 2018125019A3 TR 2017050737 W TR2017050737 W TR 2017050737W WO 2018125019 A3 WO2018125019 A3 WO 2018125019A3
Authority
WO
WIPO (PCT)
Prior art keywords
mir
insulin
diagnosis
treatment
mirnas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2017/050737
Other languages
English (en)
Other versions
WO2018125019A2 (fr
Inventor
Selda OKTAYOĞLU
Ediz COŞKUN
Merve ERCIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istanbul Ueniversitesi
Original Assignee
Istanbul Ueniversitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istanbul Ueniversitesi filed Critical Istanbul Ueniversitesi
Publication of WO2018125019A2 publication Critical patent/WO2018125019A2/fr
Publication of WO2018125019A3 publication Critical patent/WO2018125019A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne l'utilisation d'au moins un microARN choisi dans le groupe constitué de miR -18 a, miR -19 b, miR -30 d, miR -124, miR -146 a, miR -184, miR -435, miR-433-5 p et miR -503, ou d'un ADN, d'un ARNm ou d'un ARNnc associé, dans le diagnostic et le traitement de maladies liées à l'insuline telles que le diabète sucré et l'obésité.
PCT/TR2017/050737 2016-12-30 2017-12-31 Utilisation de certains miarn destinés au diagnostic et au traitement de maladies associées à l'insuline Ceased WO2018125019A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
TR2016/20327 2016-12-30
TR201620292 2016-12-30
TR2016/20292 2016-12-30
TR2016/20274 2016-12-30
TR201620274 2016-12-30
TR201620327 2016-12-30

Publications (2)

Publication Number Publication Date
WO2018125019A2 WO2018125019A2 (fr) 2018-07-05
WO2018125019A3 true WO2018125019A3 (fr) 2018-09-20

Family

ID=61024547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2017/050737 Ceased WO2018125019A2 (fr) 2016-12-30 2017-12-31 Utilisation de certains miarn destinés au diagnostic et au traitement de maladies associées à l'insuline

Country Status (1)

Country Link
WO (1) WO2018125019A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7638967B2 (ja) * 2019-08-26 2025-03-04 ピリオド ピル ベーフェー 月経周期性症状の治療
WO2022060178A1 (fr) * 2020-09-21 2022-03-24 고려대학교 산학협력단 Procédé pour la prédiction de la récurrence ou du pronostic de l'ulcère du pied diabétique en utilisant la méthylation spécifique du gène
KR102581240B1 (ko) * 2020-09-21 2023-09-22 고려대학교 산학협력단 유전자의 특이적 메틸화를 이용하여 당뇨족부궤양 재발 또는 예후를 예측하는 방법
US20230364153A1 (en) * 2020-09-24 2023-11-16 Research & Business Foundation Sungkyunkwan University Method for direct reprogramming from somatic cells into pancreatic beta cells by using microrna, and differentiation composition
CN113122536B (zh) * 2021-03-31 2023-06-20 南通大学 一种促进神经干细胞向神经元分化的长链非编码rna及其筛选方法
CN113774127B (zh) * 2021-09-24 2022-06-24 南京医科大学 血清细胞外囊泡miR-503-5p在制备2型糖尿病发病的诊断试剂盒中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078558A2 (fr) * 2010-12-06 2012-06-14 Rush University Medical Center Micro-arn en tant que nouvelles cibles thérapeutiques pour la prévention et/ou le traitement de la rétinopathie
WO2014135653A1 (fr) * 2013-03-06 2014-09-12 Royal College Of Surgeons In Ireland Diagnostic et traitement de troubles du métabolisme
WO2015095116A1 (fr) * 2013-12-17 2015-06-25 Rush University Medical Center Compositions et méthodes pour le traitement de la néphropathie diabétique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078558A2 (fr) * 2010-12-06 2012-06-14 Rush University Medical Center Micro-arn en tant que nouvelles cibles thérapeutiques pour la prévention et/ou le traitement de la rétinopathie
WO2014135653A1 (fr) * 2013-03-06 2014-09-12 Royal College Of Surgeons In Ireland Diagnostic et traitement de troubles du métabolisme
WO2015095116A1 (fr) * 2013-12-17 2015-06-25 Rush University Medical Center Compositions et méthodes pour le traitement de la néphropathie diabétique

Also Published As

Publication number Publication date
WO2018125019A2 (fr) 2018-07-05

Similar Documents

Publication Publication Date Title
WO2018125019A3 (fr) Utilisation de certains miarn destinés au diagnostic et au traitement de maladies associées à l'insuline
WO2014116729A3 (fr) Haplotypage de loci hla par séquençage ultra-profond à l'aveugle
WO2009108856A3 (fr) Signatures de microarn associées à la leucémie lymphoïde chronique humaine (llc) et leurs utilisations
WO2017156015A3 (fr) Micro-arn et leurs procédés d'utilisation
WO2013150082A8 (fr) Réplication de molécules d'acides nucléiques à base d'hybridation
WO2013107459A3 (fr) Micro-arn pour le diagnostic du cancer du pancréas et/ou le pronostic de patients atteints d'un cancer du pancréas au moyen d'échantillons de sang
JP2016526529A5 (fr)
JP2012070736A5 (fr)
WO2014052487A8 (fr) Pcr à deux amorces pour dosage multiplexe de microarn
WO2009111375A3 (fr) Traitement, diagnostic et procédé pour découvrir un antagoniste à l'aide d'arnmi spécifique de sparc
WO2015188197A3 (fr) Constructions de polynucléotides possédant des groupes bioréversibles et non bioréversibles
WO2007148235A3 (fr) Acides nucléiques apparentés au cancer
JP2016528887A5 (fr)
EP2481805A3 (fr) Procédés de différenciation entre le cancer du pancréas d'une fonction pancréatique normale et/ou de la pancréatite chronique
WO2016209862A8 (fr) Compositions d'arndb contre un gène de glucokinase (gck) et leurs procédés d'utilisation
WO2009090639A3 (fr) Composés d'arnsi et leurs utilisations
JP2017502668A5 (fr)
HK1213830A1 (zh) 用於预测醋酸格拉替雷临床反应的生物标志物
HK1200274A1 (en) Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
WO2015012541A3 (fr) Kit de diagnostic précoce de la maladie d'alzheimer
MX2017004973A (es) Metodos y composiciones para tratar a un sujeto con un oligonucleotido antisentido de smad7.
HK1212734A1 (zh) 用於检测创伤後应激障碍(ptsd)的标志物和方法
WO2015179777A3 (fr) Profils d'expression génique associés au rejet de greffe du rein subclinique
WO2012101219A3 (fr) Ensembles de miarn complexes en tant que nouveaux biomarqueurs pour des maladies pulmonaires
WO2014124155A3 (fr) Procédés d'induction de la prolifération de cardiomyocytes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17875073

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17875073

Country of ref document: EP

Kind code of ref document: A2